EvoBiotech is a biotechnology start-up working on extracellular vesicles building on more than 20 years of expertise in the field.
Our proprietary technology exploits the natural ability of EV to deliver bioactive molecules to target cells and our focus is to use plant-derived extracellular vesicles as an innovative solution to improve the efficacy of therapies and provide new delivery systems.

Latest news

GOALS

27th January 2023

Turin

EVOBIOTECH’S TECHNOLOGY FOR DRUG DELIVERY IN A NEW PUBLICATION

An Opinion paper entitled “Plant-Derived Extracellular Vesicles as a Platform for Drug Delivery” was just published in Innovations in Tissue Engineering & Regenerative Medicine. The publication describes the advantages of plant-derived extracellular vesicles as carriers and their relevance for the future of drug delivery. The complete article at the link: https://crimsonpublishers.com/iterm/pdf/ITERM.000523.pdf

GOALS

24th January 2023

Turin

EVOBIOTECH SUCCESSFULLY COMPLETED THE INCUBATION PROGRAM

Evobiotech received the recognition for the successful completion of the incubation program 2019-2022 of Incubatore d’Imprese 2i3T. Three years of growth and activities that brought the company to develop multiple therapeutic platforms using plant-derived extracellular vesicles.

BOARD AND TEAM

14th November 2022

Turin

EVOBIOTECH APPOINTS MARCO DIECI AS BOARD MEMBER AND COO

Turin, November 14th 2022 EvoBiotech S.r.l. announces the appointment of Mr. Marco Dieci as member of the Board and Chief Operating Officer. EvoBiotech is a Biotech company developing a novel technology platform using plant-derived Extracellular Vesicles (EV) aimed at improving the healing efficacy of advanced dressings and medications used in wound care treatments and at […]